Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University Health Sciences Center, Mercer University, Atlanta, GA 30341, USA.
Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University Health Sciences Center, Mercer University, Atlanta, GA 30341, USA; Department of Biomedical Sciences, School of Medicine, Mercer University Health Sciences Center, Mercer University, Macon, GA 31207, USA.
Biochem Pharmacol. 2023 Jul;213:115590. doi: 10.1016/j.bcp.2023.115590. Epub 2023 May 16.
Kidney cancer is among the 10 most common cancers, and renal cell carcinoma (RCC), which represent 90% of all kidney cancers, has the highest mortality rate of all genitourinary cancers. Papillary RCC (pRCC) is the second most frequent subtype of RCC and demonstrates distinct characteristics compared to other subtypes, including a high degree of metastasis and resistance to treatments against the more common clear cell RCC (ccRCC) subtype. Here, we demonstrate that the Free-Fatty Acid Receptor-4 (FFA4), a G protein-coupled receptor that is endogenously activated by medium-to-long chain free-fatty acids, is upregulated in pRCC compared to patient-matched normal kidney tissue, and that the expression of FFA4 increases with the degree of pathological grading of pRCC. Our data also show that FFA4 transcript is not expressed in ccRCC cell lines, but is expressed in the well-characterized metastatic pRCC cell line ACHN. Furthermore, we show that agonism of FFA4 with the selective agonist cpdA positively regulates ACHN cell migration and invasion in a manner dependent on PI3K/AKT/NF-κB signaling to COX-2 and MMP-9, with partial-dependence on EGFR transactivation. Our results also demonstrate that FFA4 agonism induces STAT-3-driven epithelial-mesenchymal transition, suggesting a significant role for FFA4 in pRCC metastasis. On the contrary, FFA4 agonism significantly reduces cell proliferation and tumor growth, suggesting that the receptor may have opposing effects on pRCC cell growth and migration. Together, our data demonstrate that FFA4 has significant functional roles in pRCC cells and may be an attractive target for study of pRCC and development of RCC pharmacotherapeutics.
肾癌是 10 大常见癌症之一,而肾细胞癌(RCC)占所有肾癌的 90%,其死亡率在所有泌尿生殖系统癌症中最高。乳头状肾细胞癌(pRCC)是 RCC 的第二大亚型,与其他亚型相比具有明显的特征,包括高度转移和对更常见的透明细胞肾细胞癌(ccRCC)亚型的治疗耐药性。在这里,我们证明了游离脂肪酸受体-4(FFA4),一种被中长链游离脂肪酸内源激活的 G 蛋白偶联受体,在 pRCC 中与患者匹配的正常肾组织相比上调,并且 FFA4 的表达随着 pRCC 的病理分级程度增加而增加。我们的数据还表明,FFA4 转录本在 ccRCC 细胞系中不表达,但在特征明确的转移性 pRCC 细胞系 ACHN 中表达。此外,我们表明,FFA4 与选择性激动剂 cpdA 的激动作用以依赖于 PI3K/AKT/NF-κB 信号传导至 COX-2 和 MMP-9 的方式正向调节 ACHN 细胞迁移和侵袭,部分依赖于 EGFR 转位激活。我们的结果还表明,FFA4 激动作用诱导 STAT-3 驱动的上皮-间充质转化,表明 FFA4 在 pRCC 转移中具有重要作用。相反,FFA4 激动作用显著降低细胞增殖和肿瘤生长,表明该受体可能对 pRCC 细胞生长和迁移具有相反的影响。总之,我们的数据表明 FFA4 在 pRCC 细胞中具有重要的功能作用,可能是研究 pRCC 和开发 RCC 药物治疗的有吸引力的靶点。